AUPH Overview

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.

Wall Street analysts forecast AUPH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AUPH is16.50 USD with a low forecast of 13.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Aurinia Pharmaceuticals Inc revenue for the last quarter amounts to 77.70M USD, increased 24.40

Aurinia Pharmaceuticals Inc. EPS for the last quarter amounts to 0.25 USD, increased 56.25

Aurinia Pharmaceuticals Inc (AUPH) has 128 emplpoyees as of June 20 2026.

Today AUPH has the market capitalization of 2.12B USD.